View More Recent Stories
-
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS)
-
H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral
-
Truist Securities Reiterates Buy Rating on Arcus Biosciences (RCUS)
-
Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
-
Arcus Biosciences (RCUS) Secures Up to $250 Million Term Loan Facility from Hercules Capital
-
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
-
Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays
-
Cantor Fitzgerald Reiterates Overweight Rating on Arcus Biosciences (RCUS)
-
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities
